Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations GlobeNewswire November 08, 2025 – Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the […]

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights

(NasdaqGM:LNTH), Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options If you purchased or acquired Lantheus securities between November 6, 2024, to August 6, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights GlobeNewswire November 08, 2025 Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options If you purchased

Minister Guilbeault highlights Budget 2025’s plan to build communities strong

The Government of Canada announces Budget 2025 measures that aim to build communities strong Changes in the global trading system are causing massive disruptions and uncertainty for Canadians. The world has changed, and Canada's economic strategy must change.Budget 2025: Canada Strongis our plan to transform our economy from one that is reliant on a single

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Varonis Systems, Inc. – VRNS

NEW YORK, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Varonis Systems, Inc. ("Varonis" or the "Company") (NASDAQ:VRNS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Varonis and certain of its officers and/or directors

BexBack Unlocks No-KYC 100x Leverage With New $100 Bonus for Beginners

SINGAPORE, Nov. 08, 2025 (GLOBE NEWSWIRE) — BexBack , a leading cryptocurrency derivatives exchange, has announced a major promotion offering new users a $100 welcome bonus and a 100% deposit match to support higher capital efficiency in crypto futures trading. As Bitcoin continues to experience sharp volatility below the $110,000 level, the platform aims to

BexBack Unlocks No-KYC 100x Leverage With New $100 Bonus for Beginners

BexBack Unlocks No-KYC 100x Leverage With New $100 Bonus for Beginners GlobeNewswire November 08, 2025 SINGAPORE, Nov. 08, 2025 (GLOBE NEWSWIRE) — BexBack , a leading cryptocurrency derivatives exchange, has announced a major promotion offering new users a $100 welcome bonus and a 100% deposit match to support higher capital efficiency in crypto futures trading.

AMGEN’S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. – RCEL

NEW YORK, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("AVITA" or the "Company") (NASDAQ:RCEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AVITA and certain of its officers and/or directors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beyond Meat, Inc. – BYND

NEW YORK, NY / ACCESS Newswire / November 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Beyond Meat, Inc. ("Beyond Meat" or the "Company") (NASDAQ:BYND). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Beyond Meat and certain of its officers

Scroll to Top